J. King

发表

Clinical and Immune Responses to Inactivated Influenza A(H1N1)pdm09 Vaccine in Children

K. Edwards, E. Walter, J. Englund, 2014, The Pediatric infectious disease journal.

Evaluation of live attenuated influenza vaccines in children 6-18 months of age: safety, immunogenicity, and efficacy. National Institute of Allergy and Infectious Diseases, Vaccine and Treatment Evaluation Program and the Wyeth-Ayerst ca Influenza Vaccine Investigators Group.

W. Gruber, F. Newman, R. Belshe, 1996, The Journal of infectious diseases.

Safety and immunogenicity of low and high doses of trivalent live cold-adapted influenza vaccine administered intranasally as drops or spray to healthy children.

D. Bernstein, R. Belshe, P. Piedra, 1998, The Journal of infectious diseases.

Safety, vaccine virus shedding and immunogenicity of trivalent, cold-adapted, live attenuated influenza vaccine administered to human immunodeficiency virus-infected and noninfected children.

Lihan K. Yan, F. Newman, R. Belshe, 2001, The Pediatric infectious disease journal.

Vaccine effectiveness of cell-culture relative to egg-based inactivated influenza vaccine during the 2017-18 influenza season

B. Fireman, Jason Asher, N. Klein, 2020, PloS one.

Dosage Escalation, Safety and Immunogenicity Study of Four Dosages of a Tetravalent Meninogococcal Polysaccharide Diphtheria Toxoid Conjugate Vaccine in Infants

M. Rennels, R. Ryall, T. Papa, 2004, The Pediatric infectious disease journal.

Surges of advanced medical support associated with influenza outbreaks

R. Hatchett, R. Lichenstein, J. Schweinle, 2017, Epidemiology and Infection.

Surge in Hospitalizations Associated With Mechanical Ventilator Use During Influenza Outbreaks

L. Magder, R. Lichenstein, J. King, 2014, Disaster Medicine and Public Health Preparedness.

The relationship between influenza outbreaks and acute ischemic heart disease in Maryland residents over a 7-year period.

L. Magder, R. Lichenstein, J. King, 2012, The Journal of infectious diseases.

Comparison of the safety, vaccine virus shedding, and immunogenicity of influenza virus vaccine, trivalent, types A and B, live cold-adapted, administered to human immunodeficiency virus (HIV)-infected and non-HIV-infected adults.

Lihan K. Yan, J. Lambert, R. Belshe, 2000, The Journal of infectious diseases.

Countywide School-Based Influenza Immunization: Direct and Indirect Impact on Student Absenteeism

L. Magder, J. King, Ginny E Cummings, 2008, Pediatrics.

Severe Illnesses Associated With Outbreaks of Respiratory Syncytial Virus and Influenza in Adults

R. Walker, R. Lichenstein, J. Schweinle, 2019, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Comparison of the safety and immunogenicity of a pneumococcal conjugate with a licensed polysaccharide vaccine in human immunodeficiency virus and non-human immunodeficiency virus-infected children.

R. Lichenstein, D. Madore, J. King, 1996, The Pediatric infectious disease journal.

Prevalence ofDientamoeba fragilis antibodies in children and recognition of a 39 kDa immunodominant protein antigen of the organism

F. Diaz-Mitoma, L. Robb, J. King, 1996, European Journal of Clinical Microbiology and Infectious Diseases.

Adjuvanted recombinant hemagglutinin H7 vaccine to highly pathogenic influenza A(H7N9) elicits high and sustained antibody responses in healthy adults

J. Treanor, R. Donis, Li-mei Chen, 2021, NPJ vaccines.

Invasive pneumococcal disease among infected and uninfected children of mothers with human immunodeficiency virus infection.

R. Tressler, J. King, R. Tressler, 1994, The Journal of pediatrics.

Safety and immunogenicity of Haemophilus influenzae-tetanus toxoid conjugate vaccine given separately or in combination with a three-component acellular pertussis vaccine combined with diphtheria and tetanus toxoids and inactivated poliovirus vaccine for the first four doses.

S. Halperin, J. King, E. Mills, 1999, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Safety and immunogenicity of a heptavalent pneumococcal conjugate vaccine in infants with human immunodeficiency virus type 1 infection.

S. Blanchard, S. Nachman, E. Abrams, 2003, Pediatrics.

Comparison of live and inactivated influenza vaccine in high risk children.

P. Wright, C. Denning, P. Gross, 1987, Vaccine.

Group-specific antibody levels surrounding invasive pneumococcal illness in children infected with human immunodeficiency virus.

W. Borkowsky, E. Shapiro, J. Clemens, 2000, The Journal of infectious diseases.

Bacteremia in febrile human immunodeficiency virus-infected children presenting to ambulatory care settings.

R. Lichenstein, J. King, J. Farley, 1998, The Pediatric infectious disease journal.

Safety and immunogenicity of a combined diphtheria, tetanus, pertussis and Haemophilus influenzae type b vaccine in young infants.

E. Rothstein, K. Reisinger, H. Bernstein, 1993, Pediatrics.

Safety, reactogenicity, and immunogenicity of a tetravalent meningococcal polysaccharide-diphtheria toxoid conjugate vaccine given to healthy adults.

M. Rennels, R. Edelman, R. Ryall, 2002, The Journal of infectious diseases.

Evaluation of the safety, reactogenicity and immunogenicity of FluBlok trivalent recombinant baculovirus-expressed hemagglutinin influenza vaccine administered intramuscularly to healthy children aged 6-59 months.

J. Hedrick, K. Reisinger, M. Cox, 2009, Vaccine.

Safety and immunogenicity of live attenuated cold-adapted influenza B/Ann Arbor/1/86 reassortant virus vaccine in infants and children.

B. Murphy, K. Edwards, P. Wright, 1991, The Journal of infectious diseases.

Community Respiratory Viruses in Individuals with Human Immunodeficiency Virus Infection

J. King, 1997, The American Journal of Medicine.

Dose escalation, safety and immunogenicity study of a tetravalent meninogococcal polysaccharide diphtheria conjugate vaccine in toddlers

M. Rennels, R. Ryall, T. Papa, 2002, The Pediatric infectious disease journal.

Antibody titers eight months after three doses of a five-valent pneumococcal conjugate vaccine in HIV and non-HIV-infected children less than two years of age.

R. Lichenstein, A. Kimura, I. Chang, 1998, Vaccine.

SAFETY AND IMMUNOGENICITY OF 3 DOSES OF A 5-VALENT PNEUMOCOCCAL CONJUGATE VACCINE (PCV) IN HIV AND NON HIV-INFECTED CHILDREN < 2 YRS OF AGE.▴ 1037

J. King, D. Hogerman, F. Malinoski, 1996, Pediatric Research.

Safety and immunogenicity of three doses of a five-valent pneumococcal conjugate vaccine in children younger than two years with and without human immunodeficiency virus infection.

R. Lichenstein, J. King, J. Farley, 1997, Pediatrics.

Phase 2 evaluation of parainfluenza type 3 cold passage mutant 45 live attenuated vaccine in healthy children 6-18 months old.

R. Karron, B. Murphy, William Rodriguez, 2004, The Journal of infectious diseases.

The immunogenicity of Haemophilus influenzae type b conjugate (HbOC) vaccine in human immunodeficiency virus‐infected and uninfected infants

P. Paradiso, J. King, J. Farley, 1995, The Pediatric infectious disease journal.

Association of influenza outbreaks with advanced pediatric medical support

R. Lichenstein, J. King, P. Bajaj, 2018, Epidemiology and Infection.

Incidence and pathogenicity of Arcanobacterium haemolyticum during a 2-year study in Ottawa.

F. Diaz-Mitoma, U. Allen, J. King, 1995, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Influenza B infection associated with encephalitis: treatment with oseltamivir.

M. Tapia, J. Straumanis, J. King, 2002, The Pediatric infectious disease journal.

A Double-Blind, Placebo-Controlled, Pilot Study of Bovine Lactoferrin Supplementation in Bottle-fed Infants

Nan Guo, J. King, S. Feigelman, 2007, Journal of pediatric gastroenterology and nutrition.

Effectiveness of school-based influenza vaccination.

L. Magder, J. Stoddard, K. Neuzil, 2006, The New England journal of medicine.

Efficacy of vaccination with live attenuated, cold-adapted, trivalent, intranasal influenza virus vaccine against a variant (A/Sydney) not contained in the vaccine.

Lihan K. Yan, F. Hayden, J. Wittes, 2000, The Journal of pediatrics.

The efficacy of live attenuated, cold-adapted, trivalent, intranasal influenzavirus vaccine in children.

F. Hayden, D. Bernstein, W. Gruber, 1998, The New England journal of medicine.

Correlates of immune protection induced by live, attenuated, cold-adapted, trivalent, intranasal influenza virus vaccine.

Lihan K. Yan, F. Hayden, D. Bernstein, 2000, The Journal of infectious diseases.

Respiratory syncytial virus illnesses in human immunodeficiency virus- and noninfected children.

J. Clemens, M. Rao, J. King, 1993, The Pediatric infectious disease journal.

Protective efficacy of a trivalent recombinant hemagglutinin protein vaccine (FluBlok®) against influenza in healthy adults: a randomized, placebo-controlled trial.

J. Treanor, M. Cox, P. Patriarca, 2011, Vaccine.

A Pilot Study of the Effectiveness of a School-Based Influenza Vaccination Program

L. Magder, J. Stoddard, J. King, 2005, Pediatrics.

Evaluation of BioThrax® and AV7909 anthrax vaccines in adults 66 years of age or older.

G. Blatner, D. Wolfe, R. Hopkins, 2020, Vaccine.

Evaluation of anthrax vaccine safety in 18 to 20 year olds: A first step towards age de-escalation studies in adolescents.

C. Quinn, J. King, E. M. Espeland, 2015, Vaccine.

Pediatrician Attitudes Concerning School-located Vaccination Clinics for Seasonal Influenza

J. King, V. Keane, Andrew R Hudson, 2012, Pediatrics.

Evaluation of a Computer-based Patient Education and Motivation Tool on Knowledge, Attitudes and Practice towards Influenza Vaccination

Richard Lichenstein, Mohit Arora, R. Lichenstein, 2009 .

Safety of the trivalent, cold-adapted influenza vaccine in preschool-aged children.

Lihan K. Yan, D. Bernstein, R. Belshe, 2002, Pediatrics.

The interferon antagonist NS2 protein of respiratory syncytial virus is an important virulence determinant for humans.

S. Madhi, R. Karron, B. Murphy, 2006, The Journal of infectious diseases.

Measles, mumps, and rubella antibodies in vaccinated Baltimore children.

T. Permutt, R. Lichenstein, J. King, 1993, American journal of diseases of children.

Adjuvanted recombinant hemagglutinin H7 vaccine to highly pathogenic influenza A(H7N9) elicits high and sustained antibody responses in healthy adults

J. Treanor, R. Donis, Li-mei Chen, 2021, npj Vaccines.

Evaluation of Fever in Infants Less Than 8 Weeks Old

P. Wright, J. King, E. Berman, 1987, Southern medical journal (Birmingham, Ala. Print).

Benefits and costs of immunizing children against influenza at school: an economic analysis based on a large-cluster controlled clinical trial.

J. Schmier, K. Nichol, Parthiv J Mahadevia, 2008, Health affairs.

Administration of Palivizumab: A Medical Provider's Perspective

J. King, V. Keane, Ginny E. Cummings, 2003, La Clinica pediatrica.

Clinical Development of Therapeutic Agents for Hospitalized Patients With Influenza: Challenges and Innovations.

R. Walker, T. Uyeki, A. Dugas, 2019, Open forum infectious diseases.

Relationship of influenza vaccine match and use rate to medically attended acute respiratory illnesses in older residents of Maryland. November 13, 2012.

L. Magder, R. Lichenstein, J. King, 2013, Vaccine.

Successful Use of Volunteers to Conduct School-located Mass Influenza Vaccination Clinics

J. King, E. Ruff, Ginny E. Cummings, 2012, Pediatrics.

Effectiveness of school-based influenza vaccination.

L. Magder, J. Stoddard, K. Neuzil, 2006, The New England journal of medicine.

Association of influenza outbreaks with advanced pediatric medical support

R. Lichenstein, J. King, P. Bajaj, 2018, Epidemiology and Infection.